



May 19, 2026

**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

Dear Sir/Madam,

**Subject :** *Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Changes in Director, Chief Financial Officer, Senior Management Personnel and Internal Auditor of the Company.*

**Stock Code :** *BSE – 539787, NSE – HCG*

**Reference :** *Disclosures under Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) read with the SEBI Master Circular No HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (“SEBI Master Circular”)*

Pursuant to Regulation 30 and other applicable provisions of the SEBI Listing Regulations read with the SEBI Master Circular, we wish to inform you that the Board of Directors of HealthCare Global Enterprises Limited (“Company”), at its meeting held on May 19, 2026, has approved the following appointments/re-appointments, based on the recommendations of the respective Committees:

**1. Re-appointment of Mr. Rajiv Maliwal (DIN: 00869035) as Non-Executive Independent Director:**

Based on the recommendation of the Nomination and Remuneration Committee (“NRC”), the Board has approved the re-appointment of Mr. Rajiv Maliwal (DIN: 00869035) as a Non-Executive Independent Director of the Company for a second term of five (5) consecutive years with effect from May 25, 2026, subject to the approval of the shareholders of the Company. Mr. Maliwal shall not be liable to retire by rotation. The disclosures required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Master Circular, including brief profile, are enclosed herewith as Annexure I.

**2. Appointment of Chief Financial Officer and Key Managerial Personnel**

Based on the recommendation of the NRC and approval of the Audit Committee, the Board has approved the appointment of Mr. Sanjeev Kumar as the Chief Financial Officer and Key Managerial



Personnel of the Company with effect from commencement of business hours on May 25, 2026. The disclosures required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Master Circular are enclosed herewith as Annexure II.

Consequent to Mr. Sanjeev Kumar assuming charge as the Chief Financial Officer of the Company, Dr. Manish Mattoo, Executive Director and Chief Executive Officer, who was appointed as the Interim Chief Financial Officer and Key Managerial Personnel of the Company pursuant to Section 203 of the Companies Act, 2013, shall cease to hold the position of Chief Financial Officer of the Company with effect from the aforesaid date.

**3. Appointment of Mr. Ravi Gothwal as AVP – Investor Relations, who shall be a Senior Management Personnel:**

Based on the recommendation of the NRC, the Board has approved the appointment of Mr. Ravi Gothwal as AVP – Investor Relations, designated as Senior Management Personnel of the Company, with effect from May 19, 2026. The disclosures required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Master Circular are enclosed herewith as Annexure III.

**4. Re-appointment of Internal Auditor:**

Based on the recommendation of the Audit Committee, the Board has approved the re-appointment of Mr. Vijay S. Shanbhag as the Internal Auditor of the Company under Section 138 of the Companies Act, 2013, for a further term of 1 (one) year with effect from May 30, 2026. The disclosures required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Master Circular are enclosed herewith as Annexure IV.

The meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 10:30 p.m.

Kindly take the above information on record and acknowledge receipt of the same.

Thanking you,

For **HealthCare Global Enterprises Limited**

**Sunu Manuel**  
Company Secretary & Compliance Officer

Encl: a/a.



**Annexure I**

**Detailed information in accordance with Regulation 30(6) of SEBI LODR Regulations read with the SEBI Master Circular No HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time, with respect to Re-appointment of Mr. Rajiv Maliwal as Non-Executive Independent Director of the Company.**

Sl. No.	Particulars	Details
01.	Reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>	Re-appointment of Mr. Rajiv Maliwal as Non-Executive Independent Director of the Company
02.	Date of <del>appointment/re-appointment/cessation</del> (as applicable) & term of appointment/re-appointment.	Date of Appointment: The reappointment is effective from May 25, 2026.  Term of appointment: Mr. Rajiv Maliwal has been re-appointed as Non-Executive Independent Director of the Company for a second term of 5 years.
03.	Brief profile (in case of appointment)	Rajiv Maliwal is the Founder and Managing Partner of Sabre Partners. He is best known for having pioneered and successfully implemented a unique private sector solution for ailing and stressed financial institutions in India (e.g. Centurion Bank, Lord Krishna Bank etc.) and more recently, in spearheading growth of healthcare and Fintech in India by providing equity capital and structuring financing innovatively.  Sabre Partners has raised three mid – market private equity funds and is now raising its fourth fund.  Prior to founding Sabre Partners in 2002, Rajiv was at Standard Chartered PLC as Global Head of Private Equity. He raised a \$300m fund, built a global team and invested internationally with a focus on financial services and technology. Between 1993 and 1998, he was with Goldman Sachs, Hong Kong and JP Morgan, Singapore and was responsible for setting up and growing the investment banking and securities firms in India with domestic partners (Goldman Sachs/Kotak Mahindra JV and JP Morgan/ICICI JV), led many M&A, Equity and Debt underwriting



		<p>and originated several private equity investments. Prior to 1993, Rajiv was with Citibank, where he was responsible for corporate and investment banking in Western India.</p> <p>Rajiv sits on the board of several companies in India and globally. He is a member of the Board of Governors of IIM, Bangalore and was a member of Stanford Parents Advisory Board for 4 years. He is a frequent speaker at a number of educational institutions and forums internationally on entrepreneurship and financial services industry amongst other areas and regularly mentors start-ups. He is also closely associated with two not-for-profit healthcare initiatives in India in the fields of mental health and eye-care.</p> <p>Rajiv graduated with an MBA from Indian Institute of Management, Bangalore in 1985 and holds a Bachelor of Engineering (Hons) degree in Mechanical Engineering from BITS, Pilani. He was awarded the IIM Bangalore, Distinguished Alumni Award in 2012.</p>
04.	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Rajiv Maliwal is not related to any of the Directors or Promoters or Promoter Group members of the Company
05.	Information as required pursuant to BSE circular ref no. LIST/ COMP/ 14/ 2018-19 and the National Stock Exchange of India with ref no. NSE/CML/2018/24, dated June 20, 2018.	Mr. Rajiv Maliwal is not debarred from holding office of a Director by virtue of any SEBI Order or any other such authority.



**Annexure II**

**Detailed information in accordance with Regulation 30(6) of SEBI LODR Regulations read with the SEBI Master Circular No HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time, with respect to the appointment of Mr. Sanjeev Kumar as the Chief Financial Officer and Key Managerial Personnel of the Company.**

Sl. No.	Particulars	Details
01.	Reason for change viz. appointment, <del>re-appointment</del> , <del>resignation</del> , <del>removal</del> , <del>death</del> or otherwise	Appointment of Mr. Sanjeev Kumar as Chief Financial Officer and Key Managerial Personnel of the Company.
02.	Date of appointment/ <del>re-appointment</del> / <del>cessation</del> (as applicable) & term of appointment/re-appointment.	Date of Appointment: Appointment is effective from May 25, 2026.  Term of appointment: Term of appointment shall commence from May 25, 2026, and shall continue as per the terms of employment as recommended by the NRC and approved by the Board of Directors, from time to time.
03.	Brief profile (in case of appointment)	Mr. Sanjeev Kumar is an accomplished senior leader with over 30 years of experience spanning telecom, travel and aviation, hospitality, and healthcare. He has a strong track record of working with growing organisations and driving transformation and delivering sustainable growth.  With over three decades of experience in finance, Sanjeev has held key leadership roles at Bharti Airtel Limited and subsequently served as Group CFO at InterGlobe Enterprises and at Medanta – The Medicity. At Medanta, he was instrumental in leading the successful IPO of Global Health Ltd. and driving strategic and financial transformation initiatives.  A seasoned finance and P&L leader, Sanjeev brings deep expertise in managing large, regulated, customer facing and capital-intensive organizations, with extensive experience in engaging with investors, regulators, and global stakeholders.



		He recently completed one year Fellow program at Harvard University, USA. An alumnus of Shri Ram College of Commerce, University of Delhi, Sanjeev is also a Chartered Accountant and a Company Secretary.
04.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.
05.	Information as required pursuant to BSE circular ref no. LIST/COMP/ 14/ 2018-19 and the National Stock Exchange of India with ref no. NSE/CML/2018/24, dated June 20, 2018.	Not Applicable.



**Annexure III**

**Detailed information in accordance with Regulation 30(6) of SEBI LODR Regulations read with the SEBI Master Circular No HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time, with respect to the appointment of Mr. Ravi Gothwal as AVP - Investor Relations, designated as Senior Management Personnel of the Company.**

Sl. No.	Particulars	Details
01.	Reason for change viz. appointment, <del>re-appointment,</del> <del>resignation,</del> <del>removal,</del> <del>death</del> or otherwise	Appointment of Mr. Ravi Gothwal as AVP - Investor Relations, designated as Senior Management Personnel of the Company.
02.	Date of appointment/ <del>re-appointment/cessation</del> (as applicable) & term of appointment/re-appointment.	Date of Appointment: Appointment is effective from May 19, 2026.  Term of appointment: Term of appointment shall commence from May 19, 2026, and shall continue as per the terms of employment as recommended by the NRC and approved by the Board of Directors, from time to time.
03.	Brief profile (in case of appointment)	Ravi brings over 13 years of rich experience across investor relations, mergers & acquisitions, and strategic consulting.  Prior to joining HCG, Ravi led Investor Relations and M&A at Medanta (Global Health Limited), where he played a key role in driving capital markets engagement, strengthening investor communication, and supporting the company’s strategic growth journey from pre-IPO to post IPO. He worked closely with senior leadership to build strong stakeholder relationships and enhance market positioning.  Earlier he held leadership roles at Churchgate Partners, advising listed companies on investor relations and capital markets strategy, and worked with KPMG in transaction advisory.  A Chartered Accountant and a graduate in B. Com (Hons.) from Shri Ram College of Commerce.



04.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.
05.	Information as required pursuant to BSE circular ref no. LIST/COMP/ 14/ 2018-19 and the National Stock Exchange of India with ref no. NSE/CML/2018/24, dated June 20, 2018.	Not Applicable.



Annexure IV

**Detailed information in accordance with Regulation 30(6) of SEBI LODR Regulations read with the SEBI Master Circular No HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time, with respect to the re-appointment of Mr. Vijay S Shanbhag, as Internal Auditor under Section 138 of the Companies Act, 2013.**

Sl. No.	Particulars	Details
01.	Reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>	Re-appointment of Mr. Vijay S Shanbhag, as Internal Auditor under Section 138 of the Companies Act, 2013.
02.	Date of <del>appointment/re-appointment/cessation</del> (as applicable) & term of appointment/re-appointment.	Date of re-appointment: The re-appointment is effective from May 30, 2026. Term of re-appointment: Term of re-appointment is for a period of 1 (one) year, which shall commence from May 30, 2026.
03.	Brief profile (in case of appointment)	<p>Vijay S. Shanbhag, re-designated as Internal Auditor of the Company with effect from December 01, 2025, joined HCG in July 2017 as Senior Manager – Internal Audit. Over the past several years, he has steadily progressed within the organization, taking on expanding responsibilities across the Internal Audit and Risk Management functions. Since April 2024, he has been leading the concurrent audit of HCG Group’s pan-India Centres, driving improved oversight, timely issue identification, and enhanced audit rigor.</p> <p>Vijay holds a Bachelor’s degree in Commerce and is a Chartered Accountant. He further brings a strong professional edge through multiple global certifications— Certified Internal Auditor (CIA), Certified Information Systems Auditor (CISA), and Certified Fraud Examiner (CFE).</p> <p>With over two decades of experience in Internal Audit and Assurance, Vijay has domain knowledge spanning financial and operational audits, risk assessment,</p>



		<p>compliance evaluations, and process enhancement initiatives.</p> <p>Before joining HCG, Vijay served within the Internal Audit and Assurance functions at Qess Corp Limited, PNB MetLife India Insurance Limited, and Satyam Computers Limited.</p>
04.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable.
05.	Information as required pursuant to BSE circular ref no. LIST/COMP/ 14/ 2018-19 and the National Stock Exchange of India with ref no. NSE/CML/2018/24, dated June 20, 2018.	Not Applicable.